当前位置： SCI文献检索 > ANNALS OF HEMATOLOGY期刊下所有文献 > Maintenance therapy in childhood acute myeloid leukemia.

Maintenance therapy in childhood acute myeloid leukemia.

Abstract：

PURPOSE:To determine whether, after very intensive induction and consolidation therapy in childhood AML, further maintenance therapy (MT) confers any advantage. PATIENTS AND METHODS:Three hundred-nine children with previously untreated AML were registered in the LAME 89/91 protocol. This three-cycle intensive regimen included an induction phase (mitoxantrone plus cytarabine) and, for non-allografted patients, two consolidation courses, one containing timed-sequential high-dose cytarabine, asparaginase and amsacrine. In the LAME 89 study, patients were given an additional MT consisting of mercaptopurine and cytarabine for 18 months. In the LAME 91 trial, patients were randomized to be given or not MT after consolidation therapy. RESULTS:Out of 309 patients, 276 (90%) achieved a complete remission. The overall survival (OS) and event-free survival at 6 years for all patients were 60% +/- 6% and 48% +/- 6%, respectively. For the complete responders after consolidation therapy, the 5-year OS was significantly better in patients randomized for no further treatment than in patients randomized for MT (81% +/- 13% vs 58% +/- 15%; p = 0.04) whilst the 5-year disease-free survival was not significantly different (60% +/- 19% vs 50% +/- 15%; p = 0.25). The improvement of OS in MT-patients appeared to be related to a higher salvage rate after relapse. CONCLUSION:Over 50% of patients can be cured of AML in childhood. In the context of a very short and drug-intensive regimen, low-dose MT, owing to the lack of improvement in disease control and the worsening of survival, should not be recommended. Over the past 20 years, the outcome of acute myeloid leukemia (AML) in children has improved substantially. In the eighties, complete remission (CR) was achieved in nearly 90% of patients but event-free survival (EFS) was poor. Myeloablative therapy followed by allogenic bone-marrow transplantation (allo BMT) from an HLA-identical sibling was demonstrated, in our experience, to be the treatment of choice for improving DFS in children with AML in first remission. The major issue was how best to maintain complete remission for patients without an HLA sibling donor. Whereas several groups continued to include low-dose MT and others decided to omit it, in 1991, our group undertook a prospective randomized trial (LAME 91 protocol), the main aim of which was to assess the efficacy of MT in addition to an intensive induction and consolidation chemotherapy. The main results have been published previously and are now updated and described in a higher number of patients.

journal_name

Ann Hematol

journal_title

Annals of hematology

authors

Perel Y,Auvrignon A,Leblanc T,Michel G,Vannier JP,Dalle JH,Gandemer V,Schmitt C,Mèchinaud F,Lamagnere JP,Piguet Ch,Couillaud G,Pautard B,Baruchel A,Leverger G,Group LAME.,French Society of Pediatric Hematology and Immunol

doi

10.1007/s00277-004-0850-2

subject

Has Abstract

pub_date

2004-01-01 00:00:00

pages

S116-9

eissn

0939-5555

issn

1432-0584

journal_volume

83 Suppl 1

pub_type

临床试验,杂志文章,随机对照试验

在线工具

Maintenance therapy in childhood acute myeloid leukemia.